An interventional study of Extracorporeal support with haemoperfusion and Conventional treatment in Hemoperfusion, Multiorgan Failure and Sepsis, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Other
Low-level interventional clinical trial to evaluate the effectiveness and safety of extracorporeal support with hemoperfusion in critical patients with septic multiorgan dysfunction syndrome.
193 studies on the registry are indexed under Multiple Organ Failure; 47 are open to participants now.
This study's planned enrollment of 48 is below the median of 88 across 90 interventional studies indexed under Multiple Organ Failure.
Browse Multiple Organ Failure studies →Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving conventional treatment for multiorganic dysfunction syndrome from septic origin.
Procedure: Conventional treatment
Patients receiving extracorporeal support with haemoperfusion for multiorganic dysfunction syndrome from septic origin.
Procedure: Extracorporeal support with haemoperfusion
Use of extracorporeal support with haemoperfusion
Conventional treatment
IL-6 plasmatic concentration
Analyze the patient's variation of IL-6 plasmatic concentration during the hemoperfusion process
Time frame: During hemoperfusion
Adverse events
Analyze the presence of adverse events during the hemoperfusion process
Time frame: During hemoperfusion
Organ failure
Analyze the number and severity of failed organs during the hemoperfusion process
Time frame: During hemoperfusion
Vasopressors dose
Analyze the patient's vasopressor dose variation during the hemoperfusion process
Time frame: During hemoperfusion
Mean arterial pressure
Analyze the patient's variation of mean arterial pressure during hemoperfusion
Time frame: During hemoperfusion
Vasopressors dose
Analyze the number of days on vasopressor support during ICU stay
Time frame: During ICU stay
Mechanical ventilation
Analyze the number of days on mechanical ventilation during ICU stay
Time frame: During ICU stay
Renal replacement therapy
Analyze the number of days on renal replacement therapy during ICU stay
Time frame: During ICU stay
ICU length of stay
Analyze the patient's length of stay in ICU
Time frame: Post-Intensive Care Unit discharge
ICU survival
Analyze the patient's survival in ICU
Time frame: Post-Intensive Care Unit discharge
Hospital stay
Analyze the patient's length of stay post-Intensive Care Unit discharge
Time frame: post-hospital discharge
Hospital survival
Analyze the patient's survival post-hospital discharge
Time frame: Post-hospital discharge
Plan to share: Yes — Background Abdominal sepsis remains a major challenge in critical care, often associated with high morbidity and mortality. Hemoadsorption therapy has been proposed as a strategy to modulate the systemic inflammatory response in septic patients. However, clinical evidence in the abdominal sepsis population is limited. Conclusions Haemoadsorption appears to be a feasible and safe intervention in patients with abdominal sepsis. Preliminary results suggest potential benefits in inflammatory modulation, organ function improvement, and mortality reduction. Larger, more robust clinical trials are required to confirm efficacy and clarify its impact on clinical outcomes. A more comprehensive and detailed analysis of the results will be provided upon completion of the study.
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Mar 2024, 12 months.
Of 28 interventional studies with no phase under Multiple Organ Failure, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Clinic of Barcelona →